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ess: k.richter@pulmoreSummary Effective inhalation therapy using pressurised metered dose inhalers
(pMDIs) and dry powder inhalers (DPIs) is the cornerstone of asthma management.
Previous studies have demonstrated difficulties in the usage of pMDIs in certain
patient groups, especially as pMDIs require the co-ordination of inhaler activation
with dose inhalation. Almost all DPIs are breath-activated and preclude the need to
co-ordinate activation with inspiration. Three key parameters for successful inhaler
use should be considered when evaluating existing or future DPI devices: (1)
compliance; (2) fine particle distribution and dependency on inspiratory flow and;
(3) clinical efficacy. A threshold mechanism which controls for a minimal inspiratory
flow rate is desirable in order to support formation of an optimal fine particle
fraction (FPF) which in turn improves lung deposition. Additionally, in order to
enhance patient compliance an optimal multidose DPI should feature a visual or
acoustic feedback of a correct inhalation. The Novolizers is a multidose refillable
DPI. It has multiple feedback mechanisms and a trigger flow valve system, which
helps to ensure correct inhalation that allows adequate lung deposition, helps to
reassure the patient that medication has been taken and might therefore improve
patient compliance. The low-to-medium airflow resistance translates into higher
peak inspiratory flow (PIF) and makes the Novolizers DPI particularly suitable for the
use in patients with reduced inspiratory flow rates. Clinical studies have shown that
children, elderly patients, adults with moderate-to-severe asthma and COPD
patients (stage IIa-III) are able to generate sufficient inspiratory flow to operate
the Novolizers effectively. In contrast previous studies with other MDPIs (e.g.
Turbuhalers or Aerolizers) demonstrated that in patient groups with severe4 Elsevier Ltd. All rights reserved.
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Figure 1 Asthmatic patients who
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inhaler activation and inspiration.
sion from Giraud and Roche.1
Successful inhaler use S23obstructive lung disease or in children with asthma optimal inspiratory flow rates are
not achieved in all patients.
r 2004 Elsevier Ltd. All rights reserved.Introduction
The majority of patients with asthma use pres-
surised metered dose inhalers (pMDIs) to deliver
medication to their lungs, but they are often
inefficient and difficult to operate. A recent study
by Giraud and Roche1 showed that misuse of pMDIs
is frequent and associated with poor asthma control
in inhaled corticosteroid (ICS)-treated asthmatics.
They assessed asthma control in 4078 patients
treated with ICSs attending general practice and
showed that the pMDI was misused by 71% of
patients; poor co-ordination was identified as the
cause of this misuse in 47% of cases.1 The study
highlighted the need to provide appropriate educa-
tion to all patients, to evaluate patient inhaler
technique and to reinforce the use of devices which
alleviate co-ordination problems in pMDI misusers.
Asthma was less stable among pMDI misusers than in
good users (Po0:001), and among misusers, asthma
was less stable in poor co-ordinators (Fig. 1).1
Common co-ordination problems encountered
whilst using pMDIs include triggering the inhaler
before inspiration or at the end of inspiration and
concluding triggering whilst holding breath.2,3 Dry
powder inhalers (DPIs) have many advantages over
MDIs. They are breath-activated, thus alleviating
co-ordination problems, are easy and convenient to
use and are environmentally friendly.
When evaluating an inhalation device, it is
important to consider patient compliance, drug
deposition within the airways, and clinical efficacy.t use Evolution unstable/
worsened
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their inhaler, asthma
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Reprinted with permis-It is essential that inhalers are easy to use, as ease
of use has implications for patient compliance.
Additionally, an inhaler device should be chosen
which maximises drug deposition in the lung.
Pressurised MDIs typically deliver only 1/3 of the
amount of drug to the lungs compared with the
newer DPIs.4,5 However, with DPIs there is a direct
relationship between the inspiratory flow rate
generated by the patient and particle size distribu-
tion; only particles of a certain diameter can be
deposited in the lungs. The aim of this article is to
identify the key features of a DPI, which make it
suitable for asthmatic patients of all ages and
severity. The Novolizers as a new multidose DPI
and the Turbuhalers as frequently used DPI are
considered in particular. The relationship between
inspiratory flow rate and particle size and how
these parameters affect deposition of drug in the
airways is assessed. Finally, clinical data examining
the suitability of the Novolizers for use in children
and comparing peak inspiratory flow rate (PIF)
generated through the Novolizers and the
Turbuhalers by adults with moderate-to-severe
asthma or chronic obstructive pulmonary disease
(COPD) is reviewed.
Factors affecting compliance
Feedback signals
The Novolizers has multiple feedback signals which
reassure the patient that sufficient drug has been
released from the device in order to deposit
adequate therapeutic agent into the lungs. The
feedback system ensures that the Novolizers is
easy to use and to teach, it guides patients through
the inhalation procedure. The success of the
release of drug powder and correct inhalation is
announced to the patient optically by a colour
change in the display window. If the patient
correctly inhales through the Novolizers, the
indicator switches from green to red. If the patient
did not generate a sufficient inspiratory flow
through the Novolizers then the indicator colour
remains green indicating that the device is still
ready to inhale from. Correct inhalation is an-
nounced to the patient also acoustically in the form
of a ‘click’, which further reassures the patients
that they have inhaled correctly and that medica-
tion has been delivered. Finally, as the carrier
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K. RichterS24particles are lactose, a sweet taste in the mouth
signals that powder has been successfully released
from the inhaler and (in combination with the other
feedback systems) further reassures the patient.
The dose counter is also indirectly linked to correct
inhalation, which might help to check the patient’s
compliance easily.
Several other MDPIs such as the Turbuhalers do
not provide direct or indirect feedback mechanisms
for the patient.Trigger flow valve
Patients are often unsure whether or not they
actually inhaled medication into their lungs. The
Novolizers reduces this uncertainty as it contains a
novel flow trigger valve system. The flow trigger
valve ensures that sufficient powder is released
under the proper flow rate conditions (in the case
of the Novolizers this flow rate is from 35 to 50 l/
min upwards)6 making the Novolizers an excellent
choice for patients with poor inhalation technique.Drug deposition within the airways
Flow rate dependency of particle size
distribution
With DPIs, particle size, respirable particle fraction
and consequently drug deposition and distribution
within the airways are critically dependent on
inspiratory flow rate achieved by the patient. This
is important as the fine particle fraction (FPF) of
therapeutic agent is directly related to its clinical
effect. Fig. 2 shows the emitted mass of 200 mg
budesonide powder for inhalation delivered by the
Novolizers which does not increase markedly as
the flow rate increased from 40 to 80 l/min.7 Even16
14
12
10
8
6
4
0
2
Em
itt
ed
 m
as
s 
[m
g]
40 60 80
100
Flow rate (I/min)
5.1
24
10.5
28
10.4
34
90
80
70
60
50
40
30
20
10
0
%
 B
ud
es
on
id
e
ca
lc
ul
at
ed
 o
n 
th
e 
em
itt
ed
 m
as
s
Budesonide 200 µg formulation (nominal mass = 10.9 mg)
flow rate corresp. to a pressure drop of 4 kPa
Emitted mass Cascade 3-5 (Fine Particle Fraction
Figure 2 Emitting performance and FPF of 200 mg
budesonide powder for inhalation using the Novolizers.
Reprinted with permission from Fyrnys et al.7the respirable FPF is relatively independent of
patients’ inspiratory flow profile.
However, with the Turbuhalers, the particle size
of the released powder is markedly affected by
patients’ flow profile8 (Fig. 3). If a patient inhales
maximally through the Turbuhalers at the begin-
ning of the inhalation manoeuvre most of the
emitted particles are between 3 and 6 mm in
diameter and so would be deposited within the
lungs. If, however, the patient inhaled slowly at
first and then gradually increased the force of their
inhalation as they progressed, then the size of
emitted particles shifts dramatically to the right. In
this scenario most of the particles are over 100 mm
in diameter which are far too large to inspire and so
would be deposited in the mouth and oropharynx
(Fig. 3).
As mentioned previously, with DPIs the in vivo
lung deposition can be influenced by patients’
inspiratory flow rate.9,10 Using a well-validated
gamma scintigraphic technique, Newman and col-
leagues11 evaluated the delivery of budesonide
(200 mg single radiolabelled dose) from the Novoli-
zers at different flow rates and compared this with
delivery from the Turbuhalers used at its optimalFigure 3 Particle spectrum of the Turbuhalers achieved
by different inspiratory flow profiles. Reprinted with
permission from Everard et al.8
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Figure 4 Scintigraphic images obtained using the Novo-
lizers at targeted inhaled flow rates of: (a) 90 l/min; (b)
60 l/min; (c) 45 l/min; and (d) the Turbuhalers at a
targeted inhaled flow rate of 60 l/min. Reprinted with
permission from Newman et al.11
Successful inhaler use S25flow rate. The Novolizers was examined at 60 and
90 l/min but also at a low flow rate (45 l/min) to
show its performance even at low flow conditions.
The study consisted of 13 healthy volunteers and
had a randomised cross-over design. Results showed
that the Novolizers achieved at least as much
deposition of budesonide in the lungs as the
Turbuhalers when used at similar inspiratory flow
rates. However at higher flow rates, the Novolizers
delivered significantly more drug to the lung and
resulted in significantly less deposition in the
mouth and oropharynx compared to the Turbuha-
lers most likely due to its lower intrinsic resis-
tance11 (Fig. 4). The pattern of regional lung
deposition in the lungs was independent of flow
rate, with good penetration to the lung periphery
at all flow rates tested. This is an important result
as the deposition of asthma drugs in the lungs is
closely linked to their subsequent clinical ef-
fects.12,13Clinical data on inspiratory flow rate
Comparison of Novolizers and Turbuhalers
To optimize inhaled treatment, the internal resis-
tance of DPIs and sufficiently high inspiratory flow
should be taken into account. Each inhaler has aunique intrinsic resistance, with values varying
widely from inhaler to inhaler. The inspiratory flow
rate which a patient can generate through a DPI is
inversely proportional to the intrinsic resistance of
the device (i.e. patients can achieve high inspira-
tory flow rates with a low resistance device).
Previous studies with different DPIs have demon-
strated that within certain patient groups, espe-
cially those patients with a high degree of airflow
obstruction or in children, not all patients are able
to reach the optimal inspiratory flow rate required
to deposit drug in the lungs.14,15 Therefore, it is
important to identify those patients who can use a
given device. By using special meters (e.g. In-Check
Dials) which mimic the internal resistance of
various DPIs or by combining a standard spirometer
with the DPI it is possible to determine the
individual peak inspiratory flow rate (PIFR)
achieved by a patient during inhalation through a
selected device.
Emeryk et al. showed that in 64 children aged
6–12 yr with different degree of airway obstruction
only 75% attained PIFR adequate for the Turbuha-
lers (460 l/min) and with regard to the Aerolizers
only 30% of patients achieved optimum PIFR
(4120 l/min).14 A study in 74 elderly COPD patients
using the Turbuhalers showed that 19% of these
patients generated a PIF of o30 l/min, 42%
generated between 30 and 40 l/min and 31%
generated between 40 and 60 l/min.15 Only 8% of
patients (n ¼ 6) were capable of generating a PIF
rate 460 l/min which is the optimal flow rate for
the Turbuhalers. By contrast based on these PIF
values, the Novolizers would be suitable for use by
90% of these patients. The low-to-medium intrinsic
resistance of the Novolizers lends itself to the
treatment of these patients with low PIF or severe
airflow obstruction. In a randomised, open-label
study Leupold and colleagues 16 assessed whether
children aged 4–11 years with stable bronchial
asthma could generate sufficient PIF through the
Novolizers. Results showed that all children, even
those aged 4–5 years, were capable of generating a
PIF greater than the trigger threshold of the
Novolizers (Fig. 4). The mean PIF (maximum of
three attempts) through the Novolizers generated
by these asthmatic children was 76 l/min which is
significantly above the technical PIF necessary to
overcome the trigger threshold. The PIF was age
dependent with the older children capable of
generating the higher PIF values with an upper
limit of about 86 l/min in the age class 8–9 years
(Fig. 5).
In a similar study, von Berg and colleagues17
investigated the PIF which could be generated
through the Novolizers (PIF-N) compared to the
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Table 1
N (ITT) PIF-T (l/
min)
PIF-N (l/
min)
PIF-N/T-
ratio
49 103728 73717 1.40
ITT: intent-to-treat; PIF-N: peak inspiratory flow rate
achieved through the Novolizers; PIF-T: peak inspiratory
flow rate achieved through the Turbuhalers.
K. RichterS26Turbuhalers (PIF-T) by children aged 6–11 years
with stable asthma. The study comprised 48
children and had an open, randomised, multi-
centre design. No treatment was administered.
Results confirmed the usability of the Novolizers
for children aged 46 years and demonstrated that
the PIF generated through the Novolizers was
significantly (Po0:0001) higher than through the
Turbuhalers in all age groups assessed (Fig. 6). In
addition, all patients were able to overcome the
trigger threshold of the Novolizers. Both PIF-N and
PIF-T were age-dependent up to 8–9 years. These
results confirm the usability of the Novolizers for
children of 6 years of age and older and demon-
strate that significantly higher PIFs can be achieved
through the Novolizers compared to the Turbuha-
lers. The authors concluded that together with the
integrated visual and acoustic feedback for correct
inhalation, the Novolizers offers several useful4-5 6-7 8-9 10-11
0
25
50
75
100
trigger
threshold
PI
F-
N
 (L
/m
in
)
Figure 5 Trigger threshold of the Novolizers and PIFR
achieved through the Novolizers (PIF-N) by children aged
4–11 years with stable bronchial asthma. Reprinted with
permission from Leupold et al.16
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Figure 6 PIFR achieved by children (6–11 years) inhaling
through the Novolizers (PIF-N) and through the Turbu-
halers (PIF-T). Reprinted with permission from Von Berg
et al.17advantages in the treatment of asthma in paedia-
tric patients.
Preliminary results from another study which
assessed PIFs generated through the Novolizers
and Turbuhalers in adults with moderate-to-severe
asthma (n ¼ 49) showed that patients were able to
generate a significantly (Po0:0001) higher PIF
through the Novolizers (103728 l/min) compared
to the Turbuhalers (73717 l/min) (Richter et al.;
data on file). Detailed data are given in Table 1. As
with the paediatric patients, all adults included in
the study were able to reach the trigger inspiratory
flow threshold required to operate the Novolizers.
Beside severe airflow obstruction in asthmatic
patients MDPIs have to be evaluated as well in
other diseases with impaired lung function and
consequently reduced inspiratory flow rates.
A study in COPD patients (n ¼ 46) produced
similar results (Table 2) (Richter et al.; data on
file). The PIF-N observed in patients with all stages
of COPD assessed (stages IIa–III) were significantly
higher than PIF-T (Po0:0001; mean difference 31 l/
min). The best predictor of PIF-N or PIF-Twas found
to be PIF at baseline, not forced expiratory volume
in 1 s (FEV1) or GOLD stage. Therefore, when
deciding on which inhaler to prescribe a COPD
patient or a patient with severe asthma a measure
of inspiratory flow rate rather than FEV1 or peak
expiratory flow rate (PEF) is more relevant.Conclusion
Considering key parameters of DPI systems includ-
ing compliance, drug deposition and achieved
inspiratory flow rates is essential for selection of
a device for different patient groups or an
individual patient. The Novolizers is a multidose
refillable DPI. It has multiple feedback mechan-
isms, a unique trigger flow valve system and low-to-
medium intrinsic resistance. Particle size is rela-
tively independent of flow profile. This means that
the Novolizers forgives poor patient technique,
improves deposition of sufficient drug into the
ARTICLE IN PRESS
Table 2 Peak inspiratory flow rate achieved by COPD patients inhaling through the Novolizers and Turbuhalers.
COPD stage N (ITT) PIF-N (l/min) PIF-T (l/min) PIF-N/T ratio
IIa 25 95722 64720 1.38
IIb 18 97715 65715 1.37
III 3 81721 60715 1.36
All 46 95719 64718 1.37
COPD: chronic obstructive pulmonary disease; ITT: intent-to-treat; PIF-N: peak inspiratory flow rate achieved through the
Novolizers; PIF-T: peak inspiratory flow rate achieved through the Turbuhalers.
Successful inhaler use S27lungs, reassures the patient that medication has
been taken and may facilitate improved patient
compliance. The low-to-medium intrinsic resis-
tance and the integrated visual and acoustic feed-
back mechanisms make the Novolizers suitable for
children, elderly patients and those patients with
impaired inspiratory flow rates due to airway
obstruction in asthma or COPD. Data from clinical
studies show higher inspiratory flow rates for the
Novolizers in all patient groups as compared to the
Turbuhalers.References
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